Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.

[1]  M. Gleave,et al.  Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. , 2015, European urology.

[2]  E. Antonarakis,et al.  The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. , 2014, European urology.

[3]  D. Dearnaley,et al.  Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. , 2014, European urology.

[4]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[5]  M. Jordan,et al.  Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells , 2014, Molecular Cancer Therapeutics.

[6]  M. Gleave,et al.  Castration-resistant prostate cancer: from new pathophysiology to new treatment. , 2014, European urology.

[7]  E. Wiemer,et al.  Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. , 2013, European journal of cancer.

[8]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[9]  J. Bono,et al.  Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Gleave,et al.  Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. , 2009, European urology.

[11]  G. Jenster,et al.  The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. , 2006, European urology.